Poractant alfa

80mg/mL (1.5mL & 3mL) suspension

Note:

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient's medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Synonyms

Curosurf®, Surfactant (porcine)

Dose and Indications

Treatment/ prevention of respiratory distress syndrome (RDS)

Endotracheal

Initial dose: 200mg/kg (2.5mL/kg)

Subsequent dose(s): 100mg/kg (1.25mL/kg) at 6 to 12 hourly intervals if required, to a maximum total of three doses (including initial dose)

Meconium Aspiration Pneumonitis

Endotracheal

The following dosing schedule[3,5] should only be used on consultant recommendation:

1st dose: 200mg/kg (2.5mL/kg) then every 6-12 hours (if required)

2nd dose: 200mg/kg (2.5mL/kg)

3rd dose: 100mg/kg (1.25mL/kg)

4th dose: 100mg/kg (1.25mL/kg)

Poractant alfa

80mg/mL (1.5mL & 3mL) suspension

Preparation and Administration

Endotracheal

Administer via an endotracheal tube. Follow appropriate Neonatal Unit specific procedures and guidelines.

- Store in the refrigerator, but warm to room temperature before use.
- Invert vial gently without shaking to re-suspend the material.
- Vial should be completely used.

Compatible Fluids

Do not dilute with any fluid

Adverse Effects

Common

Transient endotracheal tube obstruction, transient bradycardia, decreased oxygen saturation

Infrequent

Hypotension

Practice Points

- Unopened vials that have been warmed to room temperature at one time may be returned to the refrigerator within 24 hours. Vials should not be warmed and returned to the refrigerator more than once.

Reference

1. Ainsworth, S.B., Beresford, M.W., Milligan, D.W.A., Shaw, N.J., Matthews, J.N.S., Fenton, A.C. and Platt, M.W., 2000. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25–29 weeks' gestation: a randomised trial. *The Lancet*, *355*(9213), pp.1387-1392.
2. Ardell, S., Pfister, R.H. and Soll, R., 2015. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. *Cochrane Database Syst Rev*, *8.*
3. Chinese Collaborative Study Group for Neonatal Respiratory Diseases. Treatment of severe meconium aspiration with porcine surfactant: a multicentre, randomized, controlled trial. Acta Paediatrica 2005;94(7): 896–902.
4. Dizdar, E.A., Sari, F.N., Aydemir, C., Oguz, S.S., Erdeve, O., Uras, N. and Dilmen, U., 2012. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome. *American journal of perinatology*, *29*(02), pp.95-100.
5. El Shahed AI, Dargaville PA, Ohlsson A, Soll R. Surfactant for meconium aspiration syndrome in term and late preterm infants. Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No.: CD002054. DOI: 10.1002/14651858.CD002054.pub3
6. Fujii, A.M., Patel, S.M., Allen, R., Doros, G., Guo, C.Y. and Testa, S., 2010. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. *Journal of Perinatology*, *30*(10), pp.665-670.
7. Gharehbaghi, M.M., Sakha, S.H.P., Ghojazadeh, M. and Firoozi, F., 2010. Complications among premature neonates treated with beractant and poractant alfa. *The Indian Journal of Pediatrics*, *77*(7), pp.751-754.
8. Lam, B.C. and Yeung, C.Y., 1999. Surfactant lavage for meconium aspiration syndrome: a pilot study. *Pediatrics*, *103*(5), pp.1014-1018.
9. Owen, L.S., Manley, B.J., Davis, P.G. and Doyle, L.W., 2017. The evolution of modern respiratory care for preterm infants. The Lancet, 389(10079), pp.1649-1659.
10. Pfister, R.H., Soll, R. and Wiswell, T.E., 2010. Cochrane review: Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. *Evidence-Based Child Health: A Cochrane Review Journal*, *5*(1), pp.17-51.
11. Ramananthan R, Rasmussen M, Gerstmann D, Finer N, Sekar K and The North American Study Group. A Randomized, Multicenter Masked Comparison Trial of Poractant Alfa (Curosurf) verses Beractant (Survanta) in the Treatment of Respiratory Distress Syndrome in Preterm Infants. American Journal of Perinatology 2004; 21 (3): 109-119
12. Ramanathan, R., Bhatia, J.J., Sekar, K. and Ernst, F.R., 2013. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study. *Journal of Perinatology*, *33*(2), pp.119-125.
13. Singh, N., Hawley, K.L. and Viswanathan, K., 2011. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis. *Pediatrics*, *128*(6), pp.e1588-e1595.

14. Sweet, D.G., Carnielli, V., Greisen, G., Hallman, M., Ozek, E., Plavka, R., Saugstad, O.D., Simeoni, U., Speer, C.P., Vento, M. and Visser, G.H., 2017. European consensus guidelines on the management of respiratory distress syndrome-2016 update. *Neonatology*, *111*(2), pp.107-125.

Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: Health.NeoMed@sa.gov.au
Endorsed by: Commissioning and Performance, SA Health
Next review due: 05/07/2023
ISBN number: 978-1-76083-536-1
CGSQ reference: **NMG031**
Policy history: Is this a new policy (V1)? **N**
Does this policy amend or update and existing policy? **Y**
If so, which version? **V2.0**
Does this policy replace another policy with a different title? **Y**
If so, which policy (title)?

Approval Date	Version	Who approved New/Revised Version	Reason for Change
26/10/2022	V2.1	Domain Custodian, Clinical Governance, Safety and Quality	Edit of indication "Treatment/ prevention of respiratory distress syndrome (RDS) in preterm infants"
5/7/2018	V2	SA Health Safety and Quality Strategic Governance Committee	Formally reviewed in line with 5 year scheduled timeline for review.
1/11/12	V1	SA Maternal, Neonatal & Gynaecology Community of Practice	Original SA Maternal, Neonatal & Gynaecology Community of Practice approved version.